Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 46Specimen Handling 42Nivolumab 30pembrolizumab 29enzalutamide 28Gemcitabine 24Docetaxel 24apalutamide 20Prednisone 20Biopsy 19cabozantinib 17Abiraterone Acetate 17enfortumab vedotin 15Androgen Antagonists 15abiraterone 14Cisplatin 14darolutamide 13Radiotherapy 13Pluvicto 12Ipilimumab 12Mitomycin 11olaparib 10atezolizumab 10X-Rays 10erdafitinib 9cabazitaxel 9Radiation 9Carboplatin 9belzutifan 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
XRP6258 × Genitourinary × 30 days × Clear all
NCT04592237 2026-06-12

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT03419234 2026-06-03

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
223 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡